BMO maintains Novo Nordisk stock with $105 target on trial results
BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) stock, maintaining both their Outperform rating and a $105.00 price target. The endorsement comes in the wake of promising ...
Oppenheimer maintains Live Nation Outperform with $155 target
Oppenheimer analysts reiterated a positive outlook on Live Nation Entertainment shares, maintaining an Outperform rating and a $155.00 price target. The stock, currently trading near its 52-week high ...